Zobrazeno 1 - 10
of 247
pro vyhledávání: '"Alberto Righi"'
Autor:
Maria Gnoli, Marco Gambarotti, Alberto Righi, Eric Lodewijk Staals, Andrea Evangelista, Morena Tremosini, Evelise Brizola, Marina Mordenti, Manila Boarini, Manuela Locatelli, Elena Pedrini, Luca Sangiorgi
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Multiple osteochondromas is genetic disorder characterized by the formation of multiple benign cartilage-capped bone tumors, named osteochondromas, during skeletal development. The most feared complication is the secondary periphe
Externí odkaz:
https://doaj.org/article/39630631ea254982b0c1ea691e0ae7c2
Autor:
Shinji Tsukamoto, Andreas F. Mavrogenis, Yuji Nitta, Alberto Righi, Tomoya Masunaga, Kanya Honoki, Hiromasa Fujii, Akira Kido, Yuu Tanaka, Yasuhito Tanaka, Costantino Errani
Publikováno v:
Current Oncology, Vol 31, Iss 1, Pp 566-578 (2024)
Dedifferentiated chondrosarcoma (DDCS) is a high-grade subtype of chondrosarcoma with the bimorphic histological appearance of a conventional chondrosarcoma component with abrupt transition to a high-grade, non-cartilaginous sarcoma. DDCS can be radi
Externí odkaz:
https://doaj.org/article/26fea7fb8c804807a03fd196febacfb7
Autor:
Paolo Spinnato, Nicolas Papalexis, Marco Colangeli, Marco Miceli, Amandine Crombé, Anna Parmeggiani, Emanuela Palmerini, Alberto Righi, Giuseppe Bianchi
Publikováno v:
Clinics and Practice, Vol 13, Iss 6, Pp 1369-1382 (2023)
Alveolar soft part sarcoma (ASPS) is an extremely rare and aggressive soft-tissue sarcoma (STS) subtype with poor prognosis and limited response to radiation therapy and chemotherapy. Prompt recognition and referral to sarcoma centers for appropriate
Externí odkaz:
https://doaj.org/article/eff713ba9bf24424b9983b519075cb3f
Autor:
Emanuela Palmerini, Giorgio Frega, Marco Gambarotti, Tommaso Frisoni, Marilena Cesari, Alberto Bazzocchi, Marco Miceli, Davide Maria Donati, Stefano Fanti, Cristina Nanni, Stefania Benini, Alessandra Longhi, Anna Paioli, Andrea Marrari, Rossella Hakim, Alberto Righi, Toni Ibrahim
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies. Entrectinib and larotrectinib obtained unprecedented response ra
Externí odkaz:
https://doaj.org/article/65afba1c23ad453fa34d144e8c213b50
SMARCB1/INI1 loss in skull base conventional chordomas: a clinicopathological and molecular analysis
Autor:
Alberto Righi, Stefania Cocchi, Margherita Maioli, Matteo Zoli, Federica Guaraldi, Elisa Carretta, Giovanna Magagnoli, Ernesto Pasquini, Sofia Melotti, Gianfranco Vornetti, Caterina Tonon, Diego Mazzatenta, Sofia Asioli
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe loss of SMARCB1/INI1 protein has been recently described in poorly differentiated chordoma, an aggressive and rare disease variant typically arising from the skull base.MethodsRetrospective study aimed at 1) examining the differential
Externí odkaz:
https://doaj.org/article/3bda7f3ce6ed4ff6be4e96c6d3690738
Autor:
Alberto Righi, Marina Pacheco, Stefania Cocchi, Sofia Asioli, Marco Gambarotti, Davide Maria Donati, Andrea Evangelista, Maria Gnoli, Manuela Locatelli, Marina Mordenti, Manila Boarini, Evelise Brizola, Elena Pedrini, Luca Sangiorgi
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-8 (2022)
Abstract Background Secondary peripheral chondrosarcomas arising in solitary osteochondromas is an unusual complication, reported in small series. In this study, we aimed to present our experience with this rare variant of chondrosarcoma and compare
Externí odkaz:
https://doaj.org/article/45965d4def734b6fb07d33073a0c9492
Autor:
Emanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, Angela Buonadonna, Antonella Romanini, Giuseppe Badalamenti, Virginia Ferraresi, Bruno Vincenzi, Alessandro Comandone, Antonio Pizzolorusso, Antonella Brunello, Fabio Gelsomino, Tommaso De Pas, Toni Ibrahim, Lorena Gurrieri, Federica Grosso, Francesca Zanelli, Maria Abbondanza Pantaleo, Laura Milesi, Libero Ciuffreda, Vittorio Ferrari, Emanuela Marchesi, Irene Quattrini, Alberto Righi, Elisabetta Setola, Elisa Carretta, Paolo G. Casali, Piero Picci, Stefano Ferrari
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAmong sarcomas, which are rare cancers with an incidence of 24 months. Nine patients had at least one grade 3/4 adverse event, mostly being bone marrow toxicity (n=6).ConclusionsTrabectedin has some anti-tumor activity in some ultra-rare an
Externí odkaz:
https://doaj.org/article/30a46f7377b34eb8bf06a1773885869a
Autor:
Silvia Terzi, Federica Trentin, Cristiana Griffoni, Elisa Carretta, Stefano Bandiera, Cristina Ferrari, Fabio Vita, Alberto Righi, Margherita Maioli, Dario De Biase, Annalisa Monetta, Giovanni Barbanti Brodano, Gisberto Evangelisti, Marco Girolami, Valerio Pipola, Marco Gambarotti, Alessandro Gasbarrini
Publikováno v:
Diagnostics, Vol 13, Iss 12, p 2093 (2023)
Lung cancer is the second most frequently diagnosed cancer in the world, and surgery is an integral part of the treatment for spinal metastases. The aims of this retrospective study were to assess the overall survival of surgically treated patients a
Externí odkaz:
https://doaj.org/article/44e932b5268742ada0b90aaaf9dde806
Autor:
Emanuela Palmerini, Leanne L. Seeger, Marco Gambarotti, Alberto Righi, Peter Reichardt, Susan Bukata, Jean-Yves Blay, Tian Dai, Danielle Jandial, Piero Picci
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab.
Externí odkaz:
https://doaj.org/article/db75c155cbad41d9855564142b854c61
Autor:
Patrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, Alberto Righi, Giordano Nicoletti, Camilla Cristalli, Michela Pasello, Alessandro Parra, Marianna Carrabotta, Manuela Ferracin, Arianna Palladini, Marianna L. Ianzano, Veronica Giusti, Francesca Ruzzi, Mauro Magnani, Davide Maria Donati, Piero Picci, Pier-Luigi Lollini, Katia Scotlandi
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Standard therapy of osteosarcoma (OS) and Ewing sarcoma (EW) rests on cytotoxic regimes, which are largely unsuccessful in advanced patients. Preclinical models are needed to break this impasse. A panel of patient-derived xenografts (PDX) wa
Externí odkaz:
https://doaj.org/article/520fd06572ac4ed78a2083b0e3a1fa0d